Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.37 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18069434 | 0.80 | TGFBR1 (0.68) | PIK3CDPIK3CATGFBR1TDO2 | |
| SCHEMBL6792464 | 0.76 | TGFBR1 (0.53) | TGFBR1MTORMAPK14 | |
| SCHEMBL4867625 | 0.75 | TGFBR1 (0.42) | PIK3CDPIK3CATGFBR1FGFR4MAPK14 | |
| SCHEMBL4867631 | 0.75 | PIK3CD (0.40) | PIK3CDPIK3CATGFBR1TDO2FGFR4 | |
| SCHEMBL412990 | 0.75 | TGFBR1 (0.60) | TGFBR1MTORMAPK14CYP2D6TGFBR2 | |
| SCHEMBL4875633 | 0.74 | PIK3CD (0.44) | PIK3CDPIK3CATGFBR1TDO2MAPK14 | |
| SCHEMBL4864998 | 0.74 | TGFBR1 (0.47) | PIK3CDPIK3CATGFBR1MAPK14 | |
| SCHEMBL4868724 | 0.73 | TGFBR1 (0.42) | PIK3CDPIK3CATGFBR1MAPK14EGFR | |
| SCHEMBL4859601 | 0.72 | MAPK14 (0.44) | PIK3CDPIK3CATGFBR1MAPK14EGFR | |
| SCHEMBL2044546 | 0.70 | TGFBR1 (0.53) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053095-B2 | Triazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2006-05-30 | — | — | US | claimed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-20060128761-A1 | Novel triazole compounds as transforming growth factor (TGF) inhibitors | MUNCHHOF MICHAEL J | 2006-06-15 | — | — | US | disclosed |
| US-7053095-B2 | Triazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| CN-1681502-A | Novel triazole compounds as transforming growth factors (TGF) inhibitors | PFIZER PROD INC (US) | 2005-10-12 | — | — | CN | disclosed |
| US-20040110798-A1 | Novel triazole compounds as transforming growth factors (TGF) inhibitors | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110798-A1 | Novel triazole compounds as transforming growth factors (TGF) inhibitors | TGFBR1, SMAD3, TGFBR2 | PIK3CD 594/4885PIK3CA 1089/4885TGFBR1 1/4885 |
| US-20060128761-A1 | Novel triazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, SMAD3, TGFBR2 | PIK3CD 513/4885PIK3CA 984/4885TGFBR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.